| Alzheimer's disease | Amyloid-β (Aβ) plaques and neurofibrillary tangles (tau) |
| Parkinson's disease | Lewy bodies (α-synuclein) |
| ALS/FTD | TDP-43 inclusions (TARDBP) |
| Huntington's disease | Mutant huntingtin (HTT) aggregates |
| Prion diseases | PrP^Sc |
| Complex I deficiency | Observed in Parkinson's disease substantia nigra |
| ATP depletion | Leads to failure of ion pumps and excitotoxicity |
| Mitochondrial DNA mutations | Accumulate with age in neurons |
| AMPA/kainate receptors | Sodium influx and membrane depolarization |
| NMDA receptors | Calcium overload and activation of degradative enzymes |
| Metabotropic glutamate receptors | Pro-inflammatory signaling |
| Pathology | Lewy bodies (α-synuclein), dopaminergic neuron loss in substantia nigra |
| Associated Genes | MAP6, PPARGC1A, RELN, HCN1, SLC16A2, IDH2, MCU, P2RY12 |
| Therapeutic Agents | angiotensin receptor blockers, levodopa, curcumin, quercetin, aducanumab, lecanemab |
| SciDEX Hypotheses | 328 hypotheses |
| KG Connections | 3520 knowledge graph edges |
| Databases | OMIMOrphanetClinicalTrialsPubMed |